[BLUE] bluebird bio, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 64.65 Change: 2.15 (3.44%)
Ext. hours: Change: 0 (0%)

chart BLUE

Refresh chart

Strongest Trends Summary For BLUE

BLUE is in the medium-term down -10% in 2 months and down -28% below S&P in 6 months. In the long-term down -38% below S&P in 2 years and up 115% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company?s advanced product candidate is Lenti-D, which is in phase II/III studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II studies for the treatment of beta-thalassemia major and severe sickle cell disease in France, as well as a second phase I/II studies with LentiGlobin for the treatment of beta-thalassemia major in the United States. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-7.22 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0.14% Sales Growth - Q/Q-0.66% P/E-15.06
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-11.78% ROE-13.25% ROI
Current Ratio8.11 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin-294.47% Net Profit Margin-247.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities2.46 M Cash From Investing Activities-192.98 M Cash From Operating Activities-24.16 M Gross Profit
Net Profit-24.79 M Operating Profit-24.93 M Total Assets533.82 M Total Current Assets340.84 M
Total Current Liabilities42.01 M Total Debt Total Liabilities59.32 M Total Revenue6.34 M
Technical Data
High 52 week176 Low 52 week91.25 Last close125.23 Last change0.71%
RSI31.32 Average true range5.21 Beta1.76 Volume513.89 K
Simple moving average 20 days-5.49% Simple moving average 50 days-1.71% Simple moving average 200 days-3.24%
Performance Data
Performance Week4.12% Performance Month-6.53% Performance Quart-5.99% Performance Half-4.22%
Performance Year-20.34% Performance Year-to-date26.24% Volatility daily2.51% Volatility weekly5.62%
Volatility monthly11.51% Volatility yearly39.88% Relative Volume135.56% Average Volume563.09 K
New High New Low


2019-09-19 09:57:05 | Is There An Opportunity With bluebird bio, Inc.'s NASDAQ:BLUE 48% Undervaluation?

2019-09-18 09:25:00 | bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy CALD at the 13th European Pediatric Neurology Society EPNS Congress

2019-09-09 13:33:00 | Here's Why bluebird bio Fell 21.3% in August

2019-09-06 11:53:03 | FDA Grants Priority Review to Global Blood's SCD Candidate

2019-08-31 09:31:01 | Bluebird BLUE Down 19.4% Since Last Earnings Report: Can It Rebound?

2019-08-22 16:05:00 | bluebird bio Announces Investor Events in September

2019-08-22 02:18:27 | Massachusetts-based biotech company opens office in Eastlake neighborhood Photos

2019-08-16 06:20:45 | Gene therapies to test FDA's approach to regulating drugs after launch, experts say

2019-08-12 16:16:47 | Why This Biotech's $1.8 Million Gene Therapy Could Be A 'Slow Mover'

2019-08-12 10:30:00 | Bluebird Bio Stock Down as Analyst Raises Worries About Zynteglo Launch

2019-08-12 07:38:00 | Bluebird Bio Drops Following William Blair Downgrade

2019-08-08 10:25:53 | Did bluebird bio, Inc. NASDAQ:BLUE Insiders Sell Shares?

2019-08-07 17:30:00 | bluebird bio Prepares for Launch

2019-08-02 11:12:03 | bluebird's BLUE Loss Wider Than Expected, Revenues Beat

2019-08-01 19:45:11 | Bluebird Bio BLUE Reports Q2 Loss, Tops Revenue Estimates

2019-08-01 16:36:00 | bluebird bio Reports Second Quarter 2019 Financial Results and Highlights Operational Progress

2019-07-25 10:33:02 | Analysts Estimate Bluebird Bio BLUE to Report a Decline in Earnings: What to Look Out for

2019-07-15 14:46:29 | Biotech investors Wellington, RA Capital’s new funds top $700 million

2019-07-10 05:43:59 | JP Morgan: 2 Gene Therapy Stocks to Buy Now

2019-07-09 13:58:30 | 5 Immunotherapy Stocks to Keep a Close Eye On

2019-07-07 12:13:00 | Is bluebird bio a Buy?

2019-07-02 11:53:53 | Marshall Wace’s Return, AUM, and Holdings Part II

2019-06-21 08:00:00 | Where Will bluebird bio Be in 1 Year?

2019-06-18 16:14:26 | Why This Biotech's Approved Gene Therapy Won't Launch Until 2020

2019-06-18 08:04:57 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-06-17 19:17:06 | Is bluebird bio Inc BLUE A Good Stock To Buy?

2019-06-15 17:00:00 | Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?

2019-06-14 16:00:00 | Bluebird Bio’s Gene Therapy Is $1.8 Million Per Patient. The Stock Is Falling.

2019-06-14 08:54:57 | Bluebird prices gene therapy in Europe at $1.8M over 5 years

2019-06-14 05:31:00 | bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent ?-Thalassemia TDT at 24th European Hematology Association EHA Congress

2019-06-14 05:31:00 | bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease SCD at 24th European Hematology Association EHA Congress

2019-06-13 22:35:59 | Bluebird Bio prices gene therapy at nearly $1.8m

2019-06-13 21:08:21 | Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license

2019-06-12 12:14:58 | bluebird bio NASDAQ:BLUE Shareholders Have Enjoyed An Impressive 223% Share Price Gain

2019-06-10 08:06:59 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-06-06 17:04:00 | bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® autologous CD34+ cells encoding ?A-T87Q-globin gene Approval

2019-06-06 09:17:39 | Life sciences VC firm Third Rock raises $770M in its largest round ever

2019-06-04 16:16:08 | bluebird's Zynteglo Gets EU Conditional Marketing Approval

2019-06-04 15:31:00 | It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy

2019-06-03 09:25:00 | bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ autologous CD34+ cells encoding ?A-T87Q-globin gene Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent ?-Thalassemia Who Do Not Have ?0/?0 Genotype

2019-06-01 09:31:01 | Why Is Bluebird BLUE Down 15.1% Since Last Earnings Report?

2019-06-01 08:07:02 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-05-31 08:00:00 | bluebird bio Announces Investor Events in June

2019-05-30 14:34:07 | Save the Date: 11 Biotech Stocks to Put on Your Radar

2019-05-28 08:07:01 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-05-25 12:30:42 | Marshall Wace’s Latest Moves

2019-05-19 07:00:00 | Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big

2019-05-16 09:12:00 | bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent ?-thalassemia TDT and LentiGlobin Gene Therapy for Sickle Cell Disease SCD at the 24th EHA Congress

2019-05-15 14:10:36 | Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade

2019-05-15 10:49:00 | Bluebird Bio’s Pricing Plan Worries One Biotech Analyst. Here’s Why.